Bhopal Newspaper

Cytokine Release Syndrome Epidemiology Forecast till 2030

 Breaking News
  • No posts were found

Cytokine Release Syndrome Epidemiology Forecast till 2030

July 20
15:31 2020
Cytokine Release Syndrome Epidemiology Forecast till 2030

DelveInsight Buisness Research LLP
DelveInsight’s ‘Cytokine Release Syndrome Epidemiology Forecast–2030’ report delivers an in-depth understanding of the Cytokine Release Syndrome (CRS), historical and forecasted epidemiology as well as the Cytokine Release Syndrome trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.

Cytokine Release Syndrome (CRS) is an acute systemic inflammatory syndrome characterized by fever and multiple organ dysfunction that is associated with chimeric antigen receptor (CAR)-T cell therapy, therapeutic antibodies, and haploidentical allogeneic transplantation.

 

Epidemiology Segmentation in 7MM from 2017 to 2030

  • Total Number of B-cell NHL Patients receiving CAR T-Cell Therapies
  • Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies
  • Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies
  • Total Number of Patients developing Cytokine Release Syndrome (CRS) following CART therapies
  • Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade

Epidemiology Insights

  • Total number of patients who develop CRS in the 7MM was 31 in 2017
  • Total number of Hematologic patients receiving CART-therapies in the 7MM was 41 in 2017
  • Cytokine Release Syndrome cases in the United States was 31 in 2017
  • The population of CRS cases among the EU5 countries in 2018:-
    • Germany -13
    • France – 11
    • The United Kingdom – 11
    • Spain – 6 
    • Japan had Cytokine Release Syndrome cases in 2019 – 121

Scope of Cytokine Release Syndrome Report

  • The report covers the descriptive overview of Cytokine Release Syndrome (CRS), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Cytokine Release Syndrome (CRS).
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Number of B-cell NHL Patients receiving CART-Therapies, Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CART-Therapies, Total Number of Multiple Myeloma (MM) Patients receiving CART-Therapies, Total Number of Patients developing Cytokine Release Syndrome (CRS) following CART therapies, and Total Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade.

 

Request for sample pages

 

Table of contents

1. Key Insights

2. Executive Summary of Cytokine Release Syndrome (CRS)

3. Disease Background and Overview: Cytokine Release Syndrome (CRS)

3.1. Introduction

3.2. Symptoms

3.3. Causes

3.4. Risk Factors

3.5. Pathophysiology

3.6. Biomarkers

3.7. CRS in patients with COVID-19 infection

3.8. Diagnosis

3.8.1. Grading

4. Case Reports

4.1. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: A case report

4.2. The first case of cytokine release syndrome after nivolumab for gastric cancer

4.3. Multimodal therapeutic approach of Cytokine Release Syndrome developing in a child given chimeric antigen receptor-modified T-cell Infusion

5. Cytokine Release Syndrome Epidemiology and Patient Population

5.1. Key Findings

5.2. Scope

5.3. KOL Views

5.4. Multiple Myeloma Treatment Paradigm

5.5. DLBCL Treatment Paradigm

5.6. ALL Treatment Paradigm

5.7. CAR-T Cell Therapies Forecast Flow

5.8. CRS Epidemiology Methodology

5.9. Total Number of Hematologic Malignancies Patients receiving CAR-T Cell Therapies in the 7MM

5.10. Total Number of Patients develop CRS following CAR-T Cell Therapies in the 7MM

6. United States Epidemiology

6.1. Assumptions and Rationale

6.2. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in the United States

6.3. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in the United States

6.4. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in the United States

6.5. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in the United States

6.6. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in the United States

7. EU5 Epidemiology

7.1. Assumptions and Rationale

7.2. Germany Epidemiology

7.2.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Germany

7.2.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in Germany

7.2.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in Germany

7.2.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in Germany

7.2.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in Germany

7.3. France Epidemiology

7.3.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in France

7.3.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in France

7.3.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in France

7.3.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in France

7.3.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in France

7.4. Italy Epidemiology

7.4.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Italy

7.4.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in Italy

7.4.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in Italy

7.4.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in Italy

7.4.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in Italy

7.5. Spain Epidemiology

7.5.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Spain

7.5.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in Spain

7.5.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in Spain

7.5.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in Spain

7.5.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in Spain

7.6. United Kingdom Epidemiology

7.6.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in the UK

7.6.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in the UK

7.6.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in the UK

7.6.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in the UK

7.6.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in the United Kingdom

8. Japan Epidemiology

8.1. Assumptions and Rationale

8.2. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Japan

8.3. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in Japan

8.4. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in Japan

8.5. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in Japan

8.6. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in Japan

9. Appendix

9.1. Bibliography

9.2. Cytokine Release Syndrome Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: DelveInsight
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Related Articles